METROPOLIS2023-07-012023-09-30 METROPOLIS2023-07-012023-09-30 METROPOLIS2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member METROPOLIS2023-07-012023-09-30in-bse-fin:OneOperatingExpenses02Member METROPOLIS2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member METROPOLIS2023-07-012023-09-30in-bse-fin:FourOperatingExpenses02Member METROPOLIS2023-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 542650 METROPOLIS NOTLISTED Metropolis Healthcare Limited Equity 2023-04-01 2024-03-31 2023-11-04 2023-10-29 INR Lakhs Half yearly 14:00:00 17:55:00 2023-11-04 2023-11-04 true Cash Flow Indirect Not applicable Single segment Pathology Services 2023-07-01 2023-09-30 Unaudited Standalone 2854565000.00 20080000.00 2874645000.00 562923000.00 0.00 0.00 640311000.00 56197000.00 213700000.00 976603000.00 2449734000.00 424911000.00 0.00 424911000.00 130319000.00 -18197000.00 112122000.00 0.00 312789000.00 0.00 0.00 0.00 0.00 312789000.00 -10349000.00 302440000.00 0.00 0.00 102441000.00 2 6.11 6.09 0.00 0.00 6.11 6.09 1. Disclosure of segment –wise information is not applicable, as pathology services is the Company's only business segment. 2. The Board, at their meeting held on 11 February 2022, accorded in-principle approval for the voluntary liquidation of Dr. Ganesan’s Hitech Diagnostic Centre Private Limited (‘Hitech’), a wholly owned subsidiary of the Company, to be carried out under the provisions of Insolvency and Bankruptcy Code, 2016. The Board of Hitech in their meeting dated 01 April 2022 and the members of Hitech in their Extra Ordinary General meeting held on 01 April 2022 have accorded their approval for consolidation of the business of Hitech through voluntary liquidation. Pursuant to the ongoing liquidation process, the liquidator of Hitech has transferred the entire business undertaking to the Company on a going concern basis on and with effect from 04 June 2022. 3. On 02 August 2023, the Board of Directors of the Company approved grant of 75,666 Restricted Stock Units (RSU) on recommendation of Nomination and Remuneration Committee, pursuant to the Metropolis – Restrictive Stock Unit Plan – 2020 to eligible employees of the Company. This is in addition to the RSU's approved under Restrictive Stock Unit Plan – 2020 to eligible employees of the Company / subsidiaries in the previous quarters. 4. Other expenses for the quarter and six months period ended 30 September 2023 includes Rs 334.19 lakhs on account of provision for doubtful debtors as an outcome of investigation relating to a whistle blower complaint. 5. The Board of Directors of the Company has accorded their approval for entering into a Settlement agreement with the equity shareholder(s) of Star Metropolis Health Services Middle East LLC – Dubai, associate of the Company (‘ the Associate’) inter-alia to enable liquidation of the Associate as per the applicable laws. 6. On 16 November 2022, the Income Tax department conducted searches at the premises of the Company and some of its subsidiaries. No assets of the Company or its subsidiaries were seized during this process. The Company has been providing from time to time information and clarifications sought by Income Tax authorities. Subsequently, including during current quarter, the Company and some of its subsidiaries have received notices under sections 142(1), 143(2), 147 and 148 of Income Tax Act,1961, that provide for reopening of past assessment proceedings. Presently, there is no demand, and accordingly, no adjustments have been made in financial results. 7. The Board of the Company have approved interim dividend of Rs. 4 per equity shares at the meeting held on 04 November 2023. 8. On review of pattern of consumption of future economic benefits embodied in the assets, it was noted that there has been change in expected pattern of consumption of these benefits. Accordingly, with effect from 01 April 2023, the Company has changed its depreciation/amortization method to Straight Line method from Written down value method for various class of assets to reflect this change. Such a change has been accounted for as a change in an accounting estimate in accordance with Ind AS 8 “Accounting Policies, Change in Accounting Estimates and Errors”. Had Company continued previous Written Down Value Method for charging depreciation on all class of assets, charge for depreciation/amortisation for quarter and six months period ended 30 September 2023 and for future period would have been higher by Rs. 250.02 lakhs, Rs. 515.40 lakhs and Rs. 666.72 lakhs respectively and consequentially deferred tax charge on the same for the quarter and six months period ended 30 September 2023 and for future period would have been lower by Rs. 62.93 lakhs, Rs. 129.73 lakhs and Rs. 167.81 lakhs respectively. *Kindly take note that due to restriction of characters all the notes are not covered please refer full financials filed in pdf mode for notes on financial results Single segment 2023-04-01 2023-09-30 Unaudited Standalone 5417499000.00 47893000.00 5465392000.00 1090861000.00 0.00 0.00 1225030000.00 114448000.00 413564000.00 1844256000.00 4688159000.00 777233000.00 0.00 777233000.00 225039000.00 -21928000.00 203111000.00 0.00 574122000.00 0.00 0.00 0.00 0.00 574122000.00 -14442000.00 559680000.00 0.00 0.00 102441000.00 2 11.21 11.17 0.00 0.00 11.21 11.17 Laboratory testing charges 26421000.00 Other expenses 950182000.00 Laboratory testing charges 49895000.00 Other expenses 1794361000.00 1341950000.00 0.00 0.00 4154255000.00 3491132000.00 255273000.00 0.00 0.00 366516000.00 0.00 7914000.00 192660000.00 567090000.00 0.00 1927314000.00 11737014000.00 394161000.00 361061000.00 1291877000.00 180833000.00 130036000.00 62079000.00 65608000.00 2091494000.00 0.00 173565000.00 2659220000.00 0.00 0.00 14396234000.00 102441000.00 9819770000.00 9922211000.00 9922211000.00 16200000.00 0.00 1177821000.00 1194021000.00 144243000.00 740810000.00 0.00 0.00 2079074000.00 449569000.00 753000000.00 779347000.00 1981916000.00 227130000.00 113755000.00 72148000.00 2394949000.00 0.00 0.00 4474023000.00 14396234000.00 114448000.00 18563000.00 -23880000.00 0.00 -55860000.00 0.00 67249000.00 37165000.00 0.00 -103986000.00 0.00 39806000.00 0.00 413564000.00 0.00 15652000.00 0.00 -37640000.00 0.00 8942000.00 0.00 12153000.00 2341000.00 -3173000.00 0.00 0.00 0.00 -4000.00 0.00 481034000.00 1258267000.00 0.00 0.00 0.00 167741000.00 0.00 1090526000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 279285000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 49231000.00 0.00 -184198000.00 0.00 -414252000.00 0.00 0.00 0.00 0.00 0.00 0.00 20000.00 0.00 0.00 355400000.00 265119000.00 0.00 0.00 115810000.00 0.00 0.00 -736309000.00 -60035000.00 0.00 -60035000.00 240868000.00 180833000.00 -10349000.00 -14442000.00 0.00 0.00 0.00 0.00